Lurbinectedin在经治小细胞肺癌和恶性胸膜间皮瘤患者中显示临床活性和免疫调节功能
该研究前瞻性收集95例经治小细胞肺癌(SCLC)和恶性胸膜间皮瘤(MPM)患者的临床数据及外周血免疫细胞谱。SCLC队列中位无进展生存期1.5个月,客观缓解率16%;MPM队列中位无进展生存期2.8个月,12周疾病控制率29%。Lurbinectedin安全性可控,并显示免疫调节功能。
要点
- SCLC队列客观缓解率16%,12周疾病控制率28%,中位无进展生存期1.5个月。
- MPM队列12周疾病控制率29%,无部分缓解,中位无进展生存期2.8个月。
- Lurbinectedin耗竭循环经典单核细胞,与SCLC患者更好的无进展生存期相关。
核心结论
- Lurbinectedin在经治SCLC和MPM患者中安全性可控并显示临床活性,其免疫调节功能使其成为免疫联合治疗的潜在平台。
研究设计与样本
- 前瞻性收集接受Lurbinectedin治疗的SCLC和MPM患者的临床数据,共95例(SCLC 43例,MPM 52例),多数为≥3线治疗。
- 对筛查时和治疗期间的外周血样本进行流式细胞术全面免疫细胞谱分析。
主要发现
- SCLC队列中位无进展生存期1.5个月(95%CI:1.4-3.0),中位总生存期7.0个月(95%CI:4.7-未达到)。
- SCLC队列客观影像学缓解率16%,12周疾病控制率28%。
- MPM队列中位无进展生存期2.8个月(95%CI:1.4-4.2),中位总生存期7.2个月(95%CI:5.9-未达到)。
- MPM队列12周疾病控制率29%,未记录到部分缓解。
- 未观察到新的安全性信号。
关键数值与推荐
- Lurbinectedin治疗与循环经典单核细胞耗竭显著相关,该耗竭与SCLC患者更好的无进展生存期相关。
- Lurbinectedin增加CD4+和CD8+ T细胞(SCLC)以及自然杀伤细胞和自然杀伤T细胞(SCLC和MPM)的增殖,并改变循环淋巴细胞上共刺激和共抑制受体的表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. PATIENTS AND METHODS: Clinical data of patients with SCLC and MPM who were treated with lurbinectedin were prospectively collected. Comprehensive immune cell profiling by flow cytometry was performed on screening and treating peripheral blood samples. RESULTS: A total of 95 patients (43 SCLC and 52 MPM) were treated, mostly as ≥3-line of therapy. In the SCLC cohort, a median progression-free survival (mPFS) was 1.5 months (95% CI: 1.4-3.0), and median overall survival was 7.0 months (95% CI: 4.7-not reached). Objective radiological response and disease control rate after 12 weeks were 16% and 28%, respectively. In the MPM cohort, median progression-free survival was 2.8 months (95% CI: 1.4-4.2), and median overall survival was 7.2 months (95% CI: 5.9-not reached). Disease control rate after 12 weeks was 29%, whereas no partial responses were registered. No new safety signals were observed. Lurbinectedin treatment was significantly associated with the depletion of circulating classical monocytes, which correlated with a better PFS in patients with SCLC. Lurbinectedin increased the proliferation of CD4+ and CD8+ T cells (SCLC) and natural killer and natural killer T cells (SCLC and MPM) and altered co-stimulatory and co-inhibitory receptor expression on circulating lymphocytes. CONCLUSION: Lurbinectedin has a manageable safety profile and shows clinical activity in pre-treated patients with SCLC and MPM. Its immune-modulatory functions make lurbinectedin a potential platform for immunotherapy combinations.
引用
- Dumoulin DW, Cantini L, Cornelissen R, et al. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma. Eur J Cancer. 2022. PMID: 35834843. doi:10.1016/j.ejca.2022.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。